Pharmacogenomics in Stroke and Cardiovascular Disease Pharmacogenomics in Stroke and Cardiovascular Disease
This review provides an overview of the genetic variants that influence individual responses to aspirin, clopidogrel, warfarin, and statins and the clinical implications for stroke patients.Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Warfarin Best for Thrombotic Antiphospholipid Syndrome? Warfarin Best for Thrombotic Antiphospholipid Syndrome?
Patients with thrombotic antiphospholipid syndrome appear better treated with a vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, a new meta-analysis suggests.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 10, 2023 Category: Primary Care Tags: Cardiology News Source Type: news
Risk of bleeding after ground-level falls in elderly patients with atrial fibrillation and warfarin therapy - Bezak B, Vachalcova MB, Kissova V, Michalek P, Stevlik J, Jackuliak P, Stevove M, Uher T, Bohm A.
OBJECTIVES: The aim of this study was to investigate bleeding risk in patients treated with VKAs after ground-level falls, considering the type and severity of bleeding. METHODS: The study was designed as a retrospective cohort study and included a... (Source: SafetyLit)
Source: SafetyLit - January 9, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Delayed intracranial hemorrhage after head injury among elderly patients on anticoagulation seen in the emergency department - Liu S, McLeod SL, Atzema CL, Austin PC, de Wit K, Sharma S, Mittmann N, Borgundvaag B, Grewal K.
INTRODUCTION: Elderly patients on oral anticoagulation are commonly seen in emergency departments (EDs). Oral anticoagulation, particularly warfarin, is associated with an increased risk of intracranial hemorrhage after head trauma. Data on delayed bleeds ... (Source: SafetyLit)
Source: SafetyLit - October 18, 2022 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
PROACT Xa Trial of Apixaban With On-X Heart Valve Stopped PROACT Xa Trial of Apixaban With On-X Heart Valve Stopped
The DSMB cited a lack of evidence supporting noninferiority of apixaban over warfarin for valve thrombosis and thromboembolism.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 29, 2022 Category: Intensive Care Tags: Cardiology News Source Type: news
Outcomes May Be Better for Warfarin Users Who Stop Aspirin Use
FRIDAY, Sept. 23, 2022 -- Cutting aspirin use among patients treated with concomitant warfarin and lacking a clear indication for using both is associated with improved clinical outcomes, according to a study published online Sept. 19 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 23, 2022 Category: Pharmaceuticals Source Type: news
Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding
Many patients on long-term warfarin are also taking aspirin, often unnecessarily. Stopping aspirin in these patients reduces bleeding complications without any apparent harm, a new study has shown.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 22, 2022 Category: Neurology Tags: Cardiology News Source Type: news
Avoid aspirin plus warfarin to prevent bleeding risk, study reiterates
Further evidence shows that it's best not to double up on blood thinners by taking aspirin along with commonly prescribed warfarin to lessen the risk of bleeding complications. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 19, 2022 Category: Consumer Health News Source Type: news
Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease
A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS trial at ESC 2022.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 28, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Warfarin Associated With Higher UGIB Rates Compared With DOACs Warfarin Associated With Higher UGIB Rates Compared With DOACs
The risk for upper gastrointestinal bleeding was higher in men taking warfarin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 27, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
More Upper GI Bleeding Linked to Warfarin Versus DOACs
(MedPage Today) -- The use of warfarin was associated with higher rates of upper gastrointestinal bleeding, but not lower GI bleeding, compared with direct oral anticoagulants (DOACs), a population-based cohort study in Iceland showed. Among over... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 16, 2022 Category: Gastroenterology Source Type: news
CBD Could Help Cops Get Relief From Stress, Insomnia, and Chronic Pain. But Using It Puts Their Job in Jeopardy
There were moments in the past few years when Police Sgt. Brian Vaughan would have tried almost anything to break the cycle of sleeplessness that wore him down—to wash away the images, sounds, and smells of violence that stuck to his memory, and ease the constant pain that was shooting through his back. At one point, he found himself tempted to try CBD, a widely available cannabis derivative that can offer relief from many ailments. “It would have been great to be able to take it and see if it helps,” says Vaughan, a 14-year law enforcement veteran and training coordinator for the police department in Dal...
Source: TIME: Health - July 29, 2022 Category: Consumer Health News Authors: Katja Ridderbusch Tags: Uncategorized Drugs freelance healthscienceclimate Source Type: news
Warfarin Worsens Aortic Stenosis Outcomes vs DOACs, Study Hints Warfarin Worsens Aortic Stenosis Outcomes vs DOACs, Study Hints
The study, although with limitations, meshes with recent evidence that warfarin accelerates the disease and, in a new twist, may worsen survival, compared with DOACs, in patients with aortic stenosis.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 11, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news